Glafabra Therapeutics

Membership Level: Standard Community

Glafabra Therapeutics is bringing gene therapy in Fabry disease to the U.S. Fabry affects 4 million people across the globe. People with Fabry suffer kidney disease and often need a kidney transplant. To help, Glafabra is bringing to the U.S. market a gene therapy recently proven to be successful in Canadian clinical trials. The U.S. portion of the trials are expected to start in summer of 2025, where the company will bring a first-in-class therapy to Fabry patients and help them achieve a normal quality of life.

More